Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


HRT extended use not cardioprotective

Executive Summary

Continued use of hormone replacement therapy by postmenopausal women with coronary heart disease does not offer cardioprotective benefit, Wyeth-sponsored Heart and Estrogen/Progestin Replacement Study II data published in June 3 Journal of the American Medical Association show. HERS II found no reduced risk of CHD events for 1,380 women taking .625 mg of conjugated estrogens/2.5 mg of medroxyprogesterone daily during 2.7-year open-label study. HERS II is a follow-up to the 4.1 year HERS trial, which suggested a decreased risk for the third through fifth years of hormone therapy (1"The Pink Sheet" Aug. 24, 1998, p. 11)...

You may also be interested in...

Prempro Cancer Risk Addressed In 550,000 Physician Letters, Label Review

Wyeth is sending letters to approximately 550,000 physicians as part of a Prempro risk management program to address risks associated with use of the hormone combination for cardiovascular disease and osteoporosis prevention

Wyeth Premarin/Prempro Cardioprotection Claim On Hold Until 2005

Wyeth-Ayerst's pursuit of a cardioprotection claim for conjugated estrogens is likely delayed until 2005-2007 following the negative outcome of the Heart and Estrogen/Progestin Replacement Study.

ViiV Anticipates 10%-15% Switchover To Long-Term HIV Option Cabenuva

The company is optimistic about a significant portion of eligible patients opting for its newly approved long-acting HIV therapy over daily, oral antiviral therapy.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts